Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. |
| |
| Authors: | Daniel Teta Brigitte Landtwing Lüscher Jean-Jacques Gonvers Patrick Francioli Olivier Phan Michel Burnier |
| |
| Affiliation: | Division of Nephrology, CHUV, Rue du Bugnon 17, 1011 Lausanne, Switzerland. |
| |
| Abstract: | ![]()
| Introduction | In patients undergoing maintenance haemodialysis, hepatitisC virus (HCV) infection is common and may lead to severe complicationssuch as chronic hepatitis, cirrhosis and hepatocellular carcinoma.It is recommended to eradicate HCV infection in dialysis patientsawaiting renal transplantation and those with acute hepatitisC or significant chronic liver disease. Interferon- -2a in monotherapythrice weekly, which is the standard treatment for HCV infectionin this setting, has many drawbacks such as poor tolerance andmarginal response [1]. The addition of ribavirin is generallycontra-indicated in these patients due to a risk of haemolyticanaemia. Pegylated interferon was developed by attaching a largepolyethylene glycol (PEG) moiety (40 kDa) to interferon in orderto confer greater stability and prolonged systemic exposureto allow once-weekly administration [2]. In two randomized controlledtrials,
| |
| Keywords: | HCV interferon-2![]("</a) /math/alpha.gif" ALT=" {alpha}" BORDER=" 0" > polyethylene glycol |
| 本文献已被 Oxford 等数据库收录！ |
|
